USD
$0.00
(0.00%
)At Close (As of Nov 26, 2025)
$140.28M
Market Cap
-
P/E Ratio
-0.77
EPS
$1.80
52 Week High
$0.75
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$3.9M |
| Total Revenue | $4.3M |
| Cost Of Revenue | $8.3M |
| Costof Goods And Services Sold | $8.3M |
| Operating Income | -$46M |
| Selling General And Administrative | $20B |
| Research And Development | $6M |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | $296K |
| Interest Income | $322K |
| Interest Expense | $26K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.2M |
| Income Before Tax | -$46M |
| Income Tax Expense | $7.5B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$46M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$46M |
| Ebitda | -$44M |
| Net Income | -$46M |
| Field | Value (USD) |
|---|---|
| Total Assets | $31M |
| Total Current Assets | $25M |
| Cash And Cash Equivalents At Carrying Value | $22M |
| Cash And Short Term Investments | $22M |
| Inventory | $341K |
| Current Net Receivables | $405K |
| Total Non Current Assets | $5.6M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $736K |
| Intangible Assets Excluding Goodwill | $736K |
| Goodwill | $735M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $2M |
| Other Non Current Assets | - |
| Total Liabilities | $25M |
| Total Current Liabilities | $24M |
| Current Accounts Payable | $1.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $19M |
| Total Non Current Liabilities | $1.8M |
| Capital Lease Obligations | $2.7M |
| Long Term Debt | - |
| Current Long Term Debt | $19M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $21M |
| Other Current Liabilities | $2.8M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $5.4M |
| Treasury Stock | - |
| Retained Earnings | -$204M |
| Common Stock | $63K |
| Common Stock Shares Outstanding | $51M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$44M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.2M |
| Capital Expenditures | $646K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$646K |
| Cashflow From Financing | $48M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $447M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$46M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$3.9M |
| Total Revenue | $4.3M |
| Cost Of Revenue | $8.3M |
| Costof Goods And Services Sold | $8.3M |
| Operating Income | -$46M |
| Selling General And Administrative | $20B |
| Research And Development | $6M |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | $296K |
| Interest Income | $322K |
| Interest Expense | $26K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.2M |
| Income Before Tax | -$46M |
| Income Tax Expense | $7.5B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$46M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$46M |
| Ebitda | -$44M |
| Net Income | -$46M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Lucid Diagnostics Inc. is a pioneering medical diagnostic technology company based in New York, focused on revolutionizing early cancer detection and improving patient care. The company leverages cutting-edge technologies to develop innovative diagnostic tests that support informed clinical decision-making and enhance patient outcomes within the oncology field. With its dedication to addressing significant unmet needs in healthcare, Lucid Diagnostics is strategically positioned to be a vital player in the evolving medical diagnostics landscape, driving advancements that could reshape treatment methodologies and improve the quality of care for patients facing cancer.